Michael Thomas Heffernan - 19 Dec 2022 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
Director
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Michael T. Heffernan
Issuer symbol
COLL
Transactions as of
19 Dec 2022
Transactions value $
-$583,124
Form type
4
Filing time
21 Dec 2022, 18:28:36
Previous filing
14 Dec 2022
Next filing
27 Dec 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Options Exercise $58.2K +3.61K +12.87% $16.15 31.6K 19 Dec 2022 Direct
transaction COLL Common Stock Sale -$83.1K -3.61K -11.4% $23.04 28K 19 Dec 2022 Direct F1, F2
transaction COLL Common Stock Options Exercise $545K +33.8K +120.47% $16.15 61.8K 20 Dec 2022 Direct
transaction COLL Common Stock Sale -$779K -33.8K -54.64% $23.08 28K 20 Dec 2022 Direct F1, F3
transaction COLL Common Stock Options Exercise $753K +46.6K +166.29% $16.15 74.6K 21 Dec 2022 Direct
transaction COLL Common Stock Sale -$1.08M -46.6K -62.45% $23.11 28K 21 Dec 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -3.61K -3.31% $0.00 105K 19 Dec 2022 Common Stock 3.61K $16.15 Direct F5
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -33.8K -32.03% $0.00 71.6K 20 Dec 2022 Common Stock 33.8K $16.15 Direct F5
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -46.6K -65.05% $0.00 25K 21 Dec 2022 Common Stock 46.6K $16.15 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022.
F2 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).
F3 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).
F4 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4).
F5 The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable.